

1. Conference & CME programmes arranged by the Departments:

Conference:

1. Conference held in every year on Asthma Day and World TB Day.
2. Celebrate World No Tobacco Day every year.

CME Programmes:

- i) ACP Bi-monthly clinical meeting
- ii) Regular CME Programme as per departmental schedule (Twice in a week)
- iii) On World TB Day (24th March) arranged Seminar and fruits were distributed among the indoor admitted patients.
- iv) NTEP core committee meeting held at Seminar Room in Respiratory Medicine.
- v) Role planning for NTEP among patients and staff once yearly.

SL	List of ongoing research projects in each department (by students & faculties) individually and in collaborations within the academic community / Industry. The name, designation and field of expertise of Principal Investigator, Co-PI and any other related to the project must be clearly mentioned and authenticated by Head of the Institution	Funding sources and grants allocated for health and clinical research endeavours for each research project must be mentioned clearly	Overview of current research infrastructure and facilities available in medical colleges (Department wise and multidisciplinary/ multicentric)	Publication output and dissemination of research findings in the last two years.	Status of Institutional Ethics Committee (DCGI approved) with its SOP.
1.	<p>A Double-Blind, placebo-controlled study of nebulized revefenacin inhalation solution in Indian Subjects with Moderate to Very Severe chronic obstructive pulmonary disease (COPD).</p> <p>Protocol No.: REVE-SGR-3001</p> <p>PROF. (DR.) JAYDIP DEB DR. PRIYANKA RAY</p>	<p>Funded by Infoclin Consultancy (Paid by cheque to Principal, NRSMC, Kolkata) (Copy attached)</p>	<p>Available multicentric</p>	<p>On process</p>	<p>Approved</p>

2.	<p>A Phase 4, open-label, single arm, 24-week, phase4 study to evaluate the safety and efficacy of Mepolizumab 100 mg SC administered every 4 weeks in Indian participants aged ≥ 18 years with Severe eosinophilic asthma requiring oral corticosteroid treatment to Maintain asthma control (PRISM)</p> <p>Study ID: 209682/ PRISM Study PROF. (DR.) JAYDIP DEB DR. PRIYANKA RAY</p>	<p>Funded by Infoclin Consultancy (Paid by cheque to Principal, NRSMC, Kolkata) (Copy attached)</p>	<p>Ongoing multicentric</p>	<p>On process</p>	<p>Approved</p>
3.	<p>A randomized, double – blind, four – arm active and placebo – controlled dose – finding trial to evaluate the efficacy, tolerability, safety and dose response of LYT – 100 in patients with idiopathic pulmonary fibrosis (IPF)</p> <p>PROF. (DR.) JAYDIP DEB DR. PRIYANKA RAY</p>	<p>Funded by Infoclin Consultancy</p>	<p>Yet to start</p>	<p>-----</p>	<p>Approved</p>

4.	<p>A multicentre, randomized, double-blind, placebo-controlled, phase – III study to evaluate the efficacy, safety and tolerability of BMS – 986278 in participants with idiopathic pulmonary fibrosis(IPF)</p> <p>PROF. (DR.) JAYDIP DEB DR. SASWATA GHOSH</p>	Funded by Infoclin Consultancy	Yet to start	-----	Approved
	<p>A multicentre, randomized, double-blind, placebo-controlled, phase – III study to evaluate the efficacy, safety and tolerability of BMS – 986278 in participants with progressive pulmonary fibrosis (PPF)</p> <p>PROF. (DR.) JAYDIP DEB DR. SASWATA GHOSH</p>	Funded by Infoclin Consultancy	Yet to start	-----	Approved

5.	<p>Protocol Number: 212655 Protocol Title: Phase IV, 12-week, single arm, open label study evaluating the safety and efficacy of fixed dose triple combination FF/UMEC/VI administered once daily in the morning via a dry powder inhaler in participants with chronic obstructive pulmonary disease in India.</p> <p>PI:- DR. JAYDIP DEB CO-PI:- DR SASWATA GHOSH</p>	Funded by IQVIA RDS INDIA PVT LTD	Available	Pending	Approved
----	--	--------------------------------------	-----------	---------	----------